Microbix Biosystems Inc.
focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
The Company has reported its financial results for Q3/F2013, showing revenue up 35% compared with the corresponding quarter of F2012. By combining strong revenue growth with reduced operating expenses, Microbix appears on track to realize CEO Vaughn Embro-Pantalony’s goal of achieving positive cash flow and profitability of the core virology business in the near future.
Read more in the Perspective here: Microbix Biosystems eResearch
is a primary source for professional investment research, focused on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network. eResearch
posts all its reports and articles on its website, eresearch.ca
, and subscription is FREE.
eResearch: Bob Weir, CFA, Director of Research
Telephone: (416) 703-6258
Leave a comment...